The Application of Cyclopol Combined with High Frequency Jet Ventilation through Nasopharyngeal Catheter in Gastroenteroscopy of Obese Patients

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300075619

Enrollment

Unknown

Registered

2023-09-11

Start date

2023-09-11

Completion date

Unknown

Last updated

2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Interventions

Group A (propofol combined with high-frequency jet ventilation group) :High frequency jet ventilation through nasopharyngeal duct with propofol

Group B (cyclophenol combined with high-frequency jet ventilation group):High frequency jet ventilation through nasopharyngeal duct with cyclophenol

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Those who meet the indications for painless gastroscopy examination; (2) Individuals aged = 18 years and with a BMI of = 28 kg/m2; (3) Individuals classified by the American Society of Anesthesiologists (ASA) as Class I to III; (4) No contraindications for nasal intubation; (5) Those with clear awareness before examination; (6) Those who voluntarily participate in this study and sign an informed consent form

Exclusion criteria

Exclusion criteria: (1) Individuals with gastric emptying disorders, upper gastrointestinal obstruction, coagulation disorders, or malignant tumors; (2) Those with severe cardiovascular disease, respiratory system disease, or important organ dysfunction; (3) Individuals with a history of severe sleep apnea syndrome or difficult tracheal intubation anesthesia; (4) Individuals with a history of allergy or drug abuse to propofol or cyclopentanol, drug use, and alcohol abuse; (5) Long term use of antidepressants or analgesics, history of long-term use of psychotropic drugs, and cognitive impairment; (6) Severe liver and kidney dysfunction; (7) Pregnancy, lactation, or planned pregnancy; (8) Improved Mallampati grading to IV level; (9) History of nasal deformities, rhinitis, epistaxis, or nasal surgery; (10) Individuals with upper respiratory tract infections or contraindications to anesthesia;

Design outcomes

Primary

Measure	Time frame
Longyan First Affiliated Hospital of Fujian Medical University; (T0) 1 min(T2) 5 min(T3) 5 min(T4);hypoxemia;Intervention in respiratory related adverse events;	—

Secondary

Measure	Time frame
Application of vasoactive drugs;Other adverse reactions:;	—

Countries

China

Contacts

Public ContactChunfang Jian

Longyan First Affiliated Hospital of Fujian Medical University

862304000@qq.com+86 182 5047 7608

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026